Hester Biosciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 09, 2025.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported audited FY25 results with standalone revenue of ₹2,864.66 million (up ~0.5% from ₹2,851.55 million in FY24) and standalone profit after tax of ₹318.42 million (up ~17% from ₹271.59 million). Consolidated revenue grew ~2% to ₹3,111.02 million, while consolidated PAT jumped ~36% to ₹288.26 million. Q4 standalone PAT rose ~30% YoY to ₹96.35 million on revenue of ₹766.72 million. The board has recommended a dividend of ₹7 per share (70%) for FY25, subject to shareholder approval. Statutory auditor Chandulal M. Shah & Co. issued an unmodified (clean) opinion on both standalone and consolidated results.
The clean audit opinion, solid Q4 profit growth, and continued dividend payout are positive signals for shareholders. However, near-flat standalone revenue growth suggests top-line pressure, even as profitability improved. Segment data was restated with Petcare merged into Animal Healthcare, which changes prior-period comparisons.